Missouri AG aims to consolidate lawsuits against FDA’s mail abortion pill approval.
Republican Missouri Attorney General Files Lawsuit Challenging FDA Approval of Abortion Drugs by Mail
Republican Missouri Attorney General Andrew Bailey has taken a bold step by filing a lawsuit that aims to consolidate a major challenge to the Food and Drug Administration’s (FDA) approval of common abortion drugs sent by mail. This move comes in response to President Joe Biden’s Justice Department and the manufacturer of the widely used abortion drug mifepristone seeking to reverse a lower court ruling that could restrict access to the drug.
“Unelected federal bureaucrats do not have the statutory authority to approve the shipment of these dangerous chemical abortion drugs in the mail,” said Bailey.
Bailey, along with Idaho and Kansas, is calling on a Texas federal district court to combine their complaint with an existing lawsuit brought by doctors across the country, known as Alliance for Hippocratic Medicine v. FDA. The goal is to strengthen their case against the FDA’s approval of these drugs.
The Impact of Mifepristone
Mifepristone is an abortion drug that works by blocking a pregnant woman’s progesterone receptors, halting fetal development in the womb. It is often followed by the administration of misoprostol, another chemical abortifacient, to induce uterine contractions and expel the pregnancy. This combination or the use of misoprostol alone accounts for over half of all abortions.
The lawsuit filed by the three states seeks to join forces with the conservative legal firm Alliance Defending Freedom (ADF), which has a strong track record of landmark cases at the Supreme Court. ADF was involved in the recent Dobbs v. Jackson Women’s Health Organization case, which challenged decades of abortion precedent under Roe v. Wade.
While mifepristone remains available, the U.S. Court of Appeals for the 5th Circuit has suggested that restrictions should be imposed on its use. However, these restrictions will not be enforced until all legal challenges are resolved, thanks to a Supreme Court order issued in April.
The 5th Circuit has rejected the argument that the drug should be removed from the market, but it did find fault with the FDA’s changes in 2016 and 2021 that expanded access to the pills, deeming them arbitrary and capricious.
ADF senior counsel Erin Hawley expressed her support for the three states intervening in the case, stating, ”It is encouraging to see Missouri, along with Kansas and Idaho, intervene in this important case to protect the health and well-being of women and girls.”
Missouri’s complaint specifically seeks an injunction against the rollback of safety precautions in 2016, the approval of generic mifepristone in 2019, and the policies allowing these drugs to be sent by mail in 2021 and 2023.
Bailey filed the complaint in the U.S. District Court for the Northern District of Texas, where a judge initially expressed concerns about the FDA’s 2000 approval of the drug. Although the 5th Circuit later scaled back that ruling, it applied similar scrutiny to more recent changes that expanded access to the drug.
Bailey concluded, “The FDA’s guidance is not only unlawful but would cost the lives of both women and their unborn children. I am proud to be leading a coalition of states to halt the FDA’s illegal federal overreach in its tracks.”
The Washington Examiner reached out to the Justice Department for a response.
What is the basis of the doctors’ argument against the FDA’s approval of mail delivery for mifepristone and other abortion drugs?
Mplaint brought by doctors in order to challenge the FDA’s decision to approve the mail delivery of these drugs. They argue that the FDA does not have the legal authority to allow the shipment of such dangerous drugs by mail. Their aim is to restrict access to mifepristone and other abortion drugs in order to protect women’s health and safety.
Mifepristone has a significant impact on the abortion industry. By blocking progesterone receptors, it prevents the development of the fetus in the womb. This drug is often followed by the use of misoprostol, which induces contractions and expels the pregnancy. The combination of these drugs, or the use of misoprostol alone, accounts for more than half of all abortions performed.
The plaintiffs in the lawsuit argue that the FDA’s approval of these drugs being sent by mail is concerning. They believe that the shipment of mifepristone and other abortion drugs through the mail puts women at risk, as the drugs can have serious side effects and complications. The plaintiffs maintain that the FDA does not have the legal authority to approve such a delivery method and that it should be restricted in order to protect women’s health.
This lawsuit is part of a broader effort by conservative states and anti-abortion advocates to challenge the Biden administration’s policies on abortion. The filing of this lawsuit by Attorney General Bailey, along with other states, shows their determination to fight against what they perceive as the federal government overstepping its boundaries and disregarding the rights of states to regulate abortion.
The outcome of this lawsuit could have significant implications for the future of abortion access in the United States. If successful, it could lead to restrictions on the delivery of mifepristone and other abortion drugs, making it more difficult for women to access these medications. On the other hand, if the lawsuit is unsuccessful, it could further solidify the FDA’s authority in approving and regulating the shipment of abortion drugs by mail.
In conclusion, the lawsuit filed by Republican Missouri Attorney General Andrew Bailey, along with Idaho and Kansas, challenges the FDA’s approval of abortion drugs being sent by mail. They argue that the FDA does not have the legal authority to allow the shipment of these drugs and seek to protect the health and safety of women by restricting access to mifepristone and other abortion drugs. This lawsuit is part of a broader effort to challenge the Biden administration’s policies on abortion and could have significant implications for abortion access in the United States.
" Conservative News Daily does not always share or support the views and opinions expressed here; they are just those of the writer."
*As an Amazon Associate I earn from qualifying purchases
